Biotech News Butler
Rhythm Imcivree fails Phase 3 obesity trial
3 articles curated from biotech news
Rhythm’s Imcivree fails Phase 3 rare form obesity trial
Endpoints News
Mar 17, 2026
Rhythm’s Imcivree Fails Late-Stage Weight Loss Trial in Rare Obesities
BioSpace
Mar 17, 2026
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
Globle News Wire - Clinical Study
Mar 16, 2026
Share:
Post
Share
Want daily biotech news like this?
Sign up free